Risk factors for progression of chronic kidney disease

Purpose of review The present review provides an overview of the identified risk factors for chronic kidney disease (CKD) progression emphasizing the pediatric population. Recent findings Over the past 10 years, there have been significant changes to our understanding and study of preterminal kidney failure. Recent refinements in the measurement of glomerular filtration rate and glomerular filtration rate estimating equations are important tools for identification and association of risk factors for CKD progression in children. In pediatric CKD, lower level of kidney function at presentation, higher levels of proteinuria, and hypertension are known markers for a more rapid decline in glomerular filtration rate. Anemia and other reported risk factors from the pregenomic era require further study and validation. Genome-wide association studies have identified genetic loci that have provided novel genetic risk factors for CKD progression. Summary With cohort studies of children with CKD becoming mature, they have started to yield important refinements to the assessment of CKD progression. Although many of the traditional risk factors for renal progression will certainly be assessed, such cohorts will be important for evaluating novel risk factors identified by genome-wide studies.

[1]  S. Cole,et al.  Hemoglobin decline in children with chronic kidney disease: baseline results from the chronic kidney disease in children prospective cohort study. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[2]  M. Chandra,et al.  Pathogenesis of the anemia of chronic renal failure: the role of erythropoietin. , 1988, Advances in Pediatrics.

[3]  D. Marcelli,et al.  Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  Josef Coresh,et al.  Chronic kidney disease , 2012, The Lancet.

[5]  D. Levy,et al.  TCF7L2 variants associate with CKD progression and renal function in population-based cohorts. , 2008, Journal of the American Society of Nephrology : JASN.

[6]  T. Greene,et al.  Blood Pressure Control, Proteinuria, and the Progression of Renal Disease , 1995, Annals of Internal Medicine.

[7]  G. Ardissino,et al.  Proteinuria as a predictor of disease progression in children with hypodysplastic nephropathy , 2004, Pediatric Nephrology.

[8]  J. Himmelfarb,et al.  Tipping the redox balance of oxidative stress in fibrogenic pathways in chronic kidney disease , 2009, Pediatric Nephrology.

[9]  Y. Kawaguchi,et al.  Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. , 1997, Nephron.

[10]  R. Foley,et al.  Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. , 2005, Journal of the American Society of Nephrology : JASN.

[11]  Craig S. Wong,et al.  Anemia and risk of hospitalization in pediatric chronic kidney disease. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[12]  A. Levin,et al.  Effect of early correction of anemia on the progression of CKD. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  Huiman Barnhart,et al.  Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.

[14]  C. Langefeld,et al.  Genome‐wide linkage scans for renal function and albuminuria in Type 2 diabetes mellitus: the Diabetes Heart Study , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[15]  B. Warady,et al.  Morbidity and mortality in children with anemia at initiation of dialysis , 2003, Pediatric Nephrology.

[16]  P. Whelton,et al.  Blood pressure and end-stage renal disease in men. , 1996, The New England journal of medicine.

[17]  C. Zoccali,et al.  Vitamin D levels and patient outcome in chronic kidney disease. , 2009, Kidney international.

[18]  Giuseppe Remuzzi,et al.  Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. , 2005, Kidney international. Supplement.

[19]  J. Coresh,et al.  Blood lead and chronic kidney disease in the general United States population: results from NHANES III. , 2003, Kidney international.

[20]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[21]  C. McCulloch,et al.  Risk factors for end-stage renal disease: 25-year follow-up. , 2009, Archives of internal medicine.

[22]  S. Hallan,et al.  Low birth weight increases risk for end-stage renal disease. , 2008, Journal of the American Society of Nephrology : JASN.

[23]  Thomas Meitinger,et al.  Genome-wide linkage analysis of serum creatinine in three isolated European populations. , 2009, Kidney international.

[24]  J. Coresh,et al.  Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. , 2000, Kidney international.

[25]  芳充 後藤.  海外論文紹介 : Strict Blood-Pressure Control and Progression of Renal Failure in Children , 2010 .

[26]  Craig S. Wong,et al.  Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[27]  D. Reich,et al.  MYH9 is associated with nondiabetic end-stage renal disease in African Americans , 2008, Nature Genetics.

[28]  F. Schaefer,et al.  Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children , 1997, The Lancet.

[29]  D. Bowden,et al.  Genetic factors in diabetic nephropathy. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[30]  F. Schaefer,et al.  Therapeutic strategies to slow chronic kidney disease progression , 2008, Pediatric Nephrology.

[31]  Kevin V Lemley,et al.  National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. , 2003, Pediatrics.

[32]  M. Raftery,et al.  Bicarbonate supplementation slows progression of CKD and improves nutritional status. , 2009, Journal of the American Society of Nephrology : JASN.

[33]  E. Ritz,et al.  Role of calcium-phosphorous disorders in the progression of renal failure. , 2005, Kidney international. Supplement.

[34]  A. Eddy.  Progression in chronic kidney disease. , 2005, Advances in chronic kidney disease.

[35]  D. Bowden,et al.  Identification of podocin (NPHS2) gene mutations in African Americans with nondiabetic end-stage renal disease. , 2005, Kidney international.

[36]  E. A. Oliveira,et al.  Predictive factors of progression of chronic renal insufficiency: a multivariate analysis , 2003, Pediatric Nephrology.

[37]  M. Berho,et al.  Obesity and preterm birth: additive risks in the progression of kidney disease in children , 2009, Pediatric Nephrology.

[38]  Corinne Antignac,et al.  Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes. , 2002, Journal of the American Society of Nephrology : JASN.

[39]  J. Kaplan,et al.  Mutations in ACTN4, encoding α-actinin-4, cause familial focal segmental glomerulosclerosis , 2000, Nature Genetics.

[40]  L. Stevens,et al.  Testing for chronic kidney disease: a position statement from the National Kidney Foundation. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[41]  Richard J. Johnson,et al.  Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. , 2008, JAMA.

[42]  D. Feig.  Uric acid: a novel mediator and marker of risk in chronic kidney disease? , 2009, Current opinion in nephrology and hypertension.

[43]  F. Fabris,et al.  Benefits and risks of anemia correction with recombinant human erythropoietin in children maintained by hemodialysis. , 1990, The Journal of pediatrics.

[44]  I. Macdonald,et al.  Optimising nutrition in chronic renal insufficiency—progression of disease , 2004, Pediatric Nephrology.

[45]  M. Leppert,et al.  Polymorphisms in the Nonmuscle Myosin Heavy Chain 9 Gene (MYH9) Are Associated with Albuminuria in Hypertensive African Americans: The HyperGEN Study , 2009, American Journal of Nephrology.

[46]  D. Vlahov,et al.  MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis , 2008, Nature Genetics.

[47]  Yurii S. Aulchenko,et al.  Multiple loci associated with indices of renal function and chronic kidney disease , 2009, Nature Genetics.

[48]  A. Muñoz,et al.  Longitudinal formulas to estimate GFR in children with CKD. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[49]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[50]  S. Cole,et al.  The association of anemia and hypoalbuminemia with accelerated decline in GFR among adolescents with chronic kidney disease , 2007, Pediatric Nephrology.

[51]  Susan L Furth,et al.  New equations to estimate GFR in children with CKD. , 2009, Journal of the American Society of Nephrology : JASN.

[52]  J. Burke.  Low-dose subcutaneous recombinant erythropoietin in children with chronic renal failure , 1995, Pediatric Nephrology.

[53]  M. Mitsnefes,et al.  Hypertension and progression of chronic renal insufficiency in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). , 2003, Journal of the American Society of Nephrology : JASN.

[54]  Craig S. Wong,et al.  Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[55]  D. Levy,et al.  Genome-wide linkage analysis to urinary microalbuminuria in a community-based sample: the Framingham Heart Study. , 2005, Kidney international.

[56]  S. Cole,et al.  Glomerular filtration rate via plasma iohexol disappearance: pilot study for chronic kidney disease in children. , 2006, Kidney international.

[57]  A. Garg,et al.  Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. , 2003, Kidney international.

[58]  Summary of the 2007 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) Guidelines for the Management of Arterial Hypertension , 2007, Vascular health and risk management.

[59]  A. Yachie,et al.  Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy. , 2005, Clinical nephrology.

[60]  D. Vlahov,et al.  MYH 9 is a major-effect risk gene for focal segmental glomerulosclerosis , 2008 .

[61]  C. Langefeld,et al.  A genome scan for diabetic nephropathy in African Americans. , 2004, Kidney international.

[62]  G. Filler,et al.  Prevalence of complications in children with chronic kidney disease according to KDOQI. , 2006, Kidney international.

[63]  G. Ardissino,et al.  Epidemiology of chronic renal failure in children: data from the ItalKid project. , 2003, Pediatrics.

[64]  R. Elston,et al.  Genome-Wide Scans for Diabetic Nephropathy and Albuminuria in Multiethnic Populations , 2007, Diabetes.

[65]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[66]  F. Schaefer,et al.  Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. , 2004, Kidney international.

[67]  B. Fivush,et al.  Association of mortality and hospitalization with achievement of adult hemoglobin targets in adolescents maintained on hemodialysis. , 2006, Journal of the American Society of Nephrology : JASN.

[68]  Kdoqi Disclaimer.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[69]  J. Henderson,et al.  Patients with ACTN4 mutations demonstrate distinctive features of glomerular injury. , 2009, Journal of the American Society of Nephrology : JASN.

[70]  R. Chesney.  The future of pediatric nephrology , 2005, Pediatric Nephrology.

[71]  A. Anarat,et al.  Strict blood-pressure control and progression of renal failure in children. , 2009, The New England journal of medicine.

[72]  J. Kaplan,et al.  Mutations in ACTN 4 , encoding α-actinin-4 , cause familial focal segmental glomerulosclerosis , 2000 .

[73]  H. Burger,et al.  Normalization of hemoglobin level in patients with chronic kidney disease and anemia. , 2006, The New England journal of medicine.

[74]  N. Perico,et al.  Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. , 1995, Journal of the American Society of Nephrology : JASN.

[75]  T. Greene,et al.  Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. , 1995, Annals of internal medicine.

[76]  S. Parodi,et al.  Renal outcome in patients with congenital anomalies of the kidney and urinary tract. , 2009, Kidney international.

[77]  S. Cole,et al.  Blood Pressure in Children With Chronic Kidney Disease: A Report From the Chronic Kidney Disease in Children Study , 2008, Hypertension.

[78]  Yi-Jung Li,et al.  Low-level environmental exposure to lead and progressive chronic kidney diseases. , 2006, The American journal of medicine.

[79]  J. Janosky,et al.  Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders. , 2004, American journal of hypertension.

[80]  D. Levy,et al.  Genome-wide association study for renal traits in the Framingham Heart and Atherosclerosis Risk in Communities Studies , 2008, BMC Medical Genetics.

[81]  Yongmei Liu,et al.  Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. , 2009, Kidney international.

[82]  Qiong Yang,et al.  A genome-wide association for kidney function and endocrine-related traits in the NHLBI's Framingham Heart Study , 2007, BMC Medical Genetics.